The evolution of standards for experimental treatment or research

Slovenko, Ralph
April 2005
Journal of Psychiatry & Law;Spring2005, Vol. 33 Issue 1, p129
Academic Journal
Discusses the historical evolution of standards for experimental treatment or research involving human subjects. Key reason for the creation of standards; Debates on the universal standards for justifying human experiments at the Nuremberg tribunal; Basis of the U.S. Supreme Court in supporting eugenics; Legal basis of Nazi Germany in carrying out eugenic experiments; Origin of the doctrine of informed consent.


Related Articles

  • Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation. Chen, Eric X.; Tannock, Ian F. // JAMA: Journal of the American Medical Association;11/3/2004, Vol. 292 Issue 17, p2150 

    Presents an editorial on a study in this issue concerning the risks and benefits to cancer patients participating in Phase 1 clinical trials of new anticancer agents. Phase 1 trials and the patients who come to them who are usually out of normal treatment options; Expectations of the subjects;...

  • Research Compensation and the Monetarization of Medicine. Reiser, Stanley Joel // JAMA: Journal of the American Medical Association;2/2/2005, Vol. 293 Issue 5, p613 

    Comments on the debate over paying people to participate in clinical trials. Belief there are 2 facets of the question of reward; Comments on the previous article on the same topic; Debate over the body as altruistic donation or a commodity; Concern that offering money raises the chance of...

  • Clinical trials risky but necessary.  // Reactions Weekly;8/19/2006, Issue 1115, p2 

    The article discusses research being done on the health risks facing clinical research volunteers. It references a study by J. M. Drazen, published in the 2006 issue of "New England Journal of Medicine." The adverse events associated with clinical research volunteerism are mentioned. The views...

  • Serious adverse events in academic critical care research. Cook, Deborah; Lauzier, François; Rocha, Marcelo G.; Sayles, Mary Jane; Finfer, Simon // CMAJ: Canadian Medical Association Journal;4/22/2008, Vol. 178 Issue 9, p1181 

    The article discusses proposed solutions for more rational reporting of serious adverse events in academic critical care trials of drugs in common use. According to the authors, investigators must clearly describe the serious adverse events that they plan to identify and report in their protocol...

  • Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Boulanger, Denis; Dieng, Yemou; Cisse, Badara; Remoue, Franck; Capuano, Frederic; Dieme, Jean-Louis; Ndiaye, Tofene; Sokhna, Cheikh; Trape, Jean-François; Greenwood, Brian; Simondon, Francois // Transactions of the Royal Society of Tropical Medicine & Hygiene;Feb2007, Vol. 101 Issue 2, p113 

    Summary: Artesunate is a highly effective antimalarial and there is some evidence that it is also active against schistosome infections. We therefore investigated whether treatment with artesunate of acute malaria in Senegalese children had an impact on their level of infection with Schistosoma...

  • Ethical Considerations for Acupuncture and Chinese Herbal Medicine Clinical Trials: A Cross-cultural Perspective*. Zaslawski, Christopher // Evidence-based Complementary & Alternative Medicine (eCAM);Sep2010, Vol. 7 Issue 3, p295 

    Many ethical concerns revolve around the four basic principles of research: merit and integrity, respect for human beings, weighting of risk–benefit and justice. These principles form the basis for any discussion concerning human research ethics and are applicable to all areas of research...

  • At Your Own RISK. Lemonick, Michael D.; Goldstein, Andrew; Park, Alice // Time;4/22/2002, Vol. 159 Issue 16, p46 

    Focuses on the risks associated with clinical trials in medicine. Debate about the safety regulations of the trials, which often involve desperately ill patients; Expectation that the number of trials will increase, and along with that, the number of deaths; Description of various scandals such...

  • THE LEGAL PROTECTION OF TEST SUBJECTS IN CLINICAL TRIALS OF MEDICINAL PRODUCTS FOR HUMAN USE IN THE EUROPEAN UNION. De Bijl, Nicole P. Y. M. // Medicine & Law (World Association for Medical Law);2004, Vol. 23 Issue 1, p1 

    On the international as well as on the level of the European Union a legal framework has been developed on the protection of test subjects has been developed. In 2000, the Declaration of Helsinki, issued by the World Medical Association, was revised and the previous distinction between...

  • Sham surgery controls are mitigated trolleys. Albin, R. L. // Journal of Medical Ethics;Mar2005, Vol. 31 Issue 3, p149 

    Debate continues about the ethics of sham surgery controls. The most powerful argument for sham surgery controls is that rigorous experiments are needed to demonstrate safety and efficacy of surgical procedures. Without such experiments, there is danger of adopting worthless procedures in...

  • When is an inducement 'undue?' Is a payment ever coercive?  // IRB Advisor;Sep2008, Vol. 8 Issue 9, p103 

    The article discusses the issue of paying people to participate in a clinical research and about inducement undue from a bioethical perspective. It outlines three main reasons why payments to study participants are a significant issue to investigators and institutional review boards. It also...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics